Mild to moderate inhibitors of CYP3A4 (such as amiodarone) are predicted to increase eplerenone
levels, which increases the risk of hyperkalaemia.
It is generally recommended that the dose of eplerenone
should not exceed 25 mg daily in patients taking amiodarone
. Note that hypokalaemia can exacerbate the QT-prolonging effects of amiodarone